AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32441571 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 80
Study 35653117 — intervention group
Group type: COMPARATOR
Intervention: Beta carotene
Number of subjects: 3882
Study 35653117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin
Number of subjects: 3882
Study 35653117 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids
Number of subjects: 3882
Study 35653117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin (restricted to beta carotene group)
Number of subjects: 3882
Study 35653117 — intervention group
Group type: COMPARATOR
Intervention: Lutein/zeaxanthin vs beta carotene
Number of subjects: 3882
Study 35653117 — intervention group
Group type: COMPARATOR
Intervention: Low zinc
Number of subjects: 3882
Study 35653117 — intervention group
Group type: COMPARATOR
Intervention: No beta carotene
Number of subjects: 3882
Study 32641735 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children with SAM
Number of subjects: 167
Study 32641735 — intervention group
Group type: COMPARATOR
Intervention: Children with SAM without HIV
Number of subjects: 167
Study 34288609 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Number of subjects: 518
Study 34288609 — intervention group
Group type: COMPARATOR
Intervention: Oral antidepressant plus placebo (AD + PBO)
Number of subjects: 518
Study 32043763 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Fulvestrant
Number of subjects: 669
Study 32043763 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 669
Study 35943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based eight-week cognitive-behavioral therapy (CBT) treatment program
Number of subjects: 62
Study 35943958 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 62
Study 34467684 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 1102
Study 34467684 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1102
Study 35083739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol chewable tablet (1 mg/kg)
Number of subjects: 141
Study 35083739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol chewable tablet
Number of subjects: 141
Study 35083739 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride oral liquid (1 mg/kg)
Number of subjects: 141
Study 34042185 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric clinical‐radiomics model combining MRI‐reported extramural vascular invasion (EMVI) status and a Radiomics score for LVI/PNI estimation
Number of subjects: 263
Study 35190434 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based low carbohydrate diet (LCD) intervention plus standard care
Number of subjects: 100
Study 35190434 — intervention group
Group type: COMPARATOR
Intervention: standard care only
Number of subjects: 100
Study 34542313 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 6
Study 34542313 — intervention group
Group type: COMPARATOR
Intervention: Compression
Number of subjects: 6
Study 36109036 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing (POCT)
Number of subjects: 241
Study 36109036 — intervention group
Group type: COMPARATOR
Intervention: Usual care without CRP POCT
Number of subjects: 241
Study 34352597 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Meditation
Number of subjects: 55
Study 32841219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 32841219 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-azathioprine (CYC/AZA)
Number of subjects: 0
Study 34764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ketogenic diet (AKD)
Number of subjects: 60
Study 34764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 60
Study 34764215 — intervention group
Group type: COMPARATOR
Intervention: Common diet
Number of subjects: 60
Study 34764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day fasting
Number of subjects: 60
Study 34963451 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) for 1 week (Group B)
Number of subjects: 30
Study 34963451 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) for 2 weeks (Group C)
Number of subjects: 30
Study 34963451 — intervention group
Group type: COMPARATOR
Intervention: Postoperative wound management alone with gauze exchange (Group A)
Number of subjects: 30
Study 34864084 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1070
Study 34864084 — intervention group
Group type: COMPARATOR
Intervention: Non-febuxostat
Number of subjects: 1070
Study 34473033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general + epidural anesthesia
Number of subjects: 80
Study 34473033 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study 32661293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 192
Study 32661293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 36204223 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 20 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252
Study 36204223 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 12 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252
Study 36204223 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 4 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252
Study 36204223 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 252
Study 33835103 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 146
Study 33835103 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pain management medication)
Number of subjects: 146
Study 35666489 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain technique (SCS) combined with standard therapy (active range of motion, stretching exercises, and postural correction exercises)
Number of subjects: 60
Study 35666489 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only (active range of motion, stretching exercises, and postural correction exercises)
Number of subjects: 60
Study 33804967 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min aqua-cycling exercise session (WAT)
Number of subjects: 20
Study 33804967 — intervention group
Group type: EXPERIMENTAL
Intervention: land-cycling session at the same heart rate and isoenergetic to WAT (LAND-Iso)
Number of subjects: 20
Study 33804967 — intervention group
Group type: COMPARATOR
Intervention: rest condition (CONT)
Number of subjects: 20
Study 33804967 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min land-cycling exercise session (LAND)
Number of subjects: 20
Study 34919626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygomatic implant combined with 'three-dimensional ring'-supported prosthetics (group 3)
Number of subjects: 45
Study 34919626 — intervention group
Group type: COMPARATOR
Intervention: Conventional prostheses with a clasp (group 1)
Number of subjects: 45
Study 34919626 — intervention group
Group type: COMPARATOR
Intervention: Regular implant with obturator removal (group 2)
Number of subjects: 45
Study 33574139 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM titre‐based treatment with a personalised daily dose based on IgM serum titre aimed at achieving serum titres above 100 mg/dL
Number of subjects: 356
Study 33574139 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group receiving IgM enriched preparation daily for three consecutive days at the standard dose of 250 mg/kg
Number of subjects: 356
Study 32267714 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐20‐30 training (3 × 5 × 10‐s sprint followed by 30 and 20 s of low‐ to moderate‐intensity cycling, interspersed by 3 min of rest)
Number of subjects: 18
Study 32267714 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐20‐30 training
Number of subjects: 18
Study 33009187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fibrinogen concentrate (Haemocomplettan P) at a mean dose of 79 mg kg‐1 body weight
Number of subjects: 114
Study 33009187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 33009187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fibrinogen concentrate (Haemocomplettan P)
Number of subjects: 114
Study 33263136 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 250
Study 36294132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh closure
Number of subjects: 790
Study 36294132 — intervention group
Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 790
Study 34746040 — intervention group
Group type: EXPERIMENTAL
Intervention: SIM evening group (SIM addition to PEG in the evening of the day prior to colonoscopy)
Number of subjects: 419
Study 34746040 — intervention group
Group type: COMPARATOR
Intervention: SIM morning group (SIM addition to PEG in the morning of colonoscopy)
Number of subjects: 419
Study 33493256 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 120 mg
Number of subjects: 32
Study 33493256 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 300 mg
Number of subjects: 32
Study 33493256 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-push 300 mg
Number of subjects: 32
Study 33493256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32331011 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (3500 pulses at 10 Hz to left dlPFC and 1500 pulses at 1 Hz to right dlPFC)
Number of subjects: 26
Study 32331011 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 26
Study 35107141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and Gentamicin
Number of subjects: 59
Study 36178716 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS addressing physical activity and diet
Number of subjects: 5331
Study 36178716 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 5331
Study 34635000 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic taping
Number of subjects: 51
Study 34635000 — intervention group
Group type: COMPARATOR
Intervention: Rigid taping
Number of subjects: 51
Study 34635000 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 51
Study 32217010 — intervention group
Group type: EXPERIMENTAL
Intervention: Portocaval shunt (PCS)
Number of subjects: 231
Study 32217010 — intervention group
Group type: COMPARATOR
Intervention: No portocaval shunt (Control)
Number of subjects: 231
Study 36178864 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels before and after hemodialysis
Number of subjects: 84
Study 36178864 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis treatment
Number of subjects: 84
Study 34669907 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified measurement method
Number of subjects: 88
Study 34669907 — intervention group
Group type: COMPARATOR
Intervention: Standard measurement method
Number of subjects: 88
Study 32501814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-containing gel with 5% urea applied twice daily for 17 days
Number of subjects: 20
Study 32501814 — intervention group
Group type: COMPARATOR
Intervention: Untreated control forearm
Number of subjects: 20
Study 616115932 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) administered via a mostly self‐administered, tablet‐based system within 72 hours of hospitalization.
Number of subjects: 79
Study 616115932 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of GA results to treating clinicians within 24 hours of GA administration.
Number of subjects: 79
Study 35660128 — intervention group
Group type: EXPERIMENTAL
Intervention: FEE intervention
Number of subjects: 1260
Study 35660128 — intervention group
Group type: EXPERIMENTAL
Intervention: FEE + MFG interventions
Number of subjects: 1260
Study 35660128 — intervention group
Group type: COMPARATOR
Intervention: Control condition (bolstered standard of care)
Number of subjects: 1260
Study 33249198 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 890
Study 33249198 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 890
Study 34125060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transducer hand-carried ultrasound (HCU)
Number of subjects: 29
Study 34125060 — intervention group
Group type: COMPARATOR
Intervention: Multiple transducer cart-based ultrasound (CBU)
Number of subjects: 29
Study 32512752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 237
Study 32512752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet (LGID)
Number of subjects: 237
Study 32512752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean diet (LGIMD)
Number of subjects: 237
Study 32512752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 237
Study 32512752 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe NAFLD subjects
Number of subjects: 237
Study 34878412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 574
Study 34878412 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula
Number of subjects: 574
Study 32391167 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Soul and Spirit intervention
Number of subjects: 12
Study 32391167 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Soul and Spirit Plus (includes faith-based text messages)
Number of subjects: 12
Study 32391167 — intervention group
Group type: COMPARATOR
Intervention: Control arm (information leaflets)
Number of subjects: 12
Study 32391167 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 12
Study 35588737 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐1 levels in Group 3 (severe NAFLD)
Number of subjects: 316
Study 35588737 — intervention group
Group type: EXPERIMENTAL
Intervention: SDSIGF1 levels in Group 3 (severe NAFLD)
Number of subjects: 316
Study 35588737 — intervention group
Group type: EXPERIMENTAL
Intervention: SDSIGF1 levels
Number of subjects: 316
Study 35588737 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Diameter, FPG, ALT, AST, GGT
Number of subjects: 316
Study 35588737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative values in all groups
Number of subjects: 316
Study 34746161 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation at day 1 (WMT-DAY1)
Number of subjects: 19
Study 34746161 — intervention group
Group type: COMPARATOR
Intervention: Washed Microbiota Transplantation at day 8 (WMT-DAY8)
Number of subjects: 19
Study 34746161 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical remission rate at day 15 (WMT-DAY1)
Number of subjects: 19
Study 34746161 — intervention group
Group type: COMPARATOR
Intervention: Clinical remission rate at day 15 (WMT-DAY8)
Number of subjects: 19
Study 36109035 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, multidisciplinary and personalised post‐ICU care
Number of subjects: 2250
Study 36109035 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2250
Study 36161640 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-guided FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Number of subjects: 100
Study 36161640 — intervention group
Group type: COMPARATOR
Intervention: Landmark approach FICB with 15 mL bupivacaine + 10 mL 2% lidocaine
Number of subjects: 100
Study 32379071 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity
Number of subjects: 843
Study 32379071 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 843
Study 35737144 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu plus Longgu Muli decoction with five-element music therapy
Number of subjects: 120
Study 35737144 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram tablets (Control)
Number of subjects: 120
Study 32925478 — intervention group
Group type: EXPERIMENTAL
Intervention: AED-guided CPR
Number of subjects: 42
Study 32925478 — intervention group
Group type: COMPARATOR
Intervention: dispatcher-assisted CPR
Number of subjects: 42
Study 35698101 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oxycodone
Number of subjects: 96
Study 35698101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 35698101 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained study team (arm A)
Number of subjects: 96
Study 35698101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained to maximize placebo responses (arm B)
Number of subjects: 96
Study 35698101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained to minimize placebo responses (arm C)
Number of subjects: 96
Study 32598090 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and information
Number of subjects: 70
Study 32598090 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 70
Study 35420291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic newborns (n=21) with cord blood pH below 7.25
Number of subjects: 42
Study 35420291 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21) with cord blood pH above 7.25
Number of subjects: 42
Study 35420291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic newborns (n=21)
Number of subjects: 42
Study 35420291 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 42
Study 33441058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amphotericin B twice daily
Number of subjects: 84
Study 33441058 — intervention group
Group type: COMPARATOR
Intervention: Nebulized amphotericin B 3 times daily
Number of subjects: 84
Study 34402029 — intervention group
Group type: EXPERIMENTAL
Intervention: GBCS model (10-year sex-specific CVD risk prediction model including age, systolic blood pressure, use of antihypertensive medication, smoking, and diabetes)
Number of subjects: 15000
Study 34402029 — intervention group
Group type: COMPARATOR
Intervention: Framingham model
Number of subjects: 15000
Study 34402029 — intervention group
Group type: COMPARATOR
Intervention: China-PAR model
Number of subjects: 15000
Study 34406318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on five variables (age, female gender, NYHA functional classification score >3, left atrial diameter, body mass index)
Number of subjects: 1742
Study 34406318 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation and test models
Number of subjects: 1742
Study 32721213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 5 mL every 2 weeks (cohort 08)
Number of subjects: 26
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: OrienX010 (8×10^7 pfu/mL) intratumoral injections, up to 10 mL every 2 weeks (cohort 09)
Number of subjects: 26
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: OrienX010 (combined cohorts)
Number of subjects: 26
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected lesions
Number of subjects: 26
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-injected lesions
Number of subjects: 26
Study 35383116 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant lung metastases
Number of subjects: 26
Study 34556320 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730
Study 34556320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 36280151 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated radiation therapy (1.8 Gy daily to PTV + 0.6 Gy boost to GTV, total 45 Gy to PTV and 60 Gy to GTV in 25 fractions over 5 weeks)
Number of subjects: 266
Study 36280151 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (2 Gy daily to PTV, total 44 Gy to PTV and 60 Gy to GTV in 30 fractions over 6 weeks)
Number of subjects: 266
Study 33887120 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient intervention based on individualized haemodynamic assessment and teleconsultations.
Number of subjects: 605
Study 33887120 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (control).
Number of subjects: 605
Study 32468646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg orally once daily for 26 weeks
Number of subjects: 37
Study 32468646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg orally once daily for another 26 weeks
Number of subjects: 37
Study 32468646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (both doses)
Number of subjects: 37
Study 32468646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 34598314 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+CM (n=25)
Number of subjects: 75
Study 34598314 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+XDM (n=25)
Number of subjects: 75
Study 34598314 — intervention group
Group type: COMPARATOR
Intervention: CAF (control group, n=25)
Number of subjects: 75
Study 36014916 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of DHA from algal oil per day
Number of subjects: 160
Study 36014916 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule per day
Number of subjects: 160
Study 33043737 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaptivCRT algorithm
Number of subjects: 0
Study 33043737 — intervention group
Group type: COMPARATOR
Intervention: Traditional CRT programming
Number of subjects: 0
Study 33210335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 84
Study 33210335 — intervention group
Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 84
Study 32128938 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness uncertainty
Number of subjects: 263
Study 32128938 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and avoidant coping strategies
Number of subjects: 263